Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company exploring new ways to treat inflammatory and immune-related diseases, including alternatives to topical steroids.
For decades there have been no new effective treatment options for the disorders Edesa is addressing.
Inhibiting the Inflammation Cascade
Allergic Contact Dermatitis
Our lead product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. In two clinical studies, this topical therapy has demonstrated significant improvement of multiple symptoms in contact dermatitis patients. Edesa also intends to expand the utility of our sPLA2 inhibitor technology across multiple indications.
Countering Hyper-Immune Responses
Addressing the Global Health Crisis
We have prioritized the study of our novel monoclonal antibodies in moderate to severe COVID-19 patients, where inflammation and injury to the lungs is often the result of an overactive immune response, sometimes described as a “cytokine storm.” Our antibody therapies are intended to inhibit this cytokine storm and the inflammation, fluid accumulation and lung injury it causes.